Loading...
Chronic hepatitis C virus (HCV) infection not only increases risk for chronic kidney disease but also risks for graft loss and mortality after kidney transplantation. Interferon-based anti-HCV treatment in patients receiving a kidney transplant has been associated with acute graft loss. Small studies suggest that direct-acting antivirals (DAAs) are safe and effective in these patients.
In an industry-funded, open-label randomized study, researchers evaluated the safety and efficacy of the interferon-free and ribavirin-free regimen of fixed-dose ledipasvir (90 mg) and sofosbuvir (400 mg) given daily for 12 or 24 weeks to kidney transplant recipients with HCV genotype 1 or 4 infection and an estimated glomerular filtration rate ≥40 mL/min. The…